Logo

American Heart Association

  2
  0


Final ID:

Incretin Analogues for Addressing Multisystem Morbidity

  • Neuen, Brendon  ( George Institute for Global Health , Newtown , New South Wales , Australia )
  • Ndumele, Chiadi  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
  • Author Disclosures:
    Brendon Neuen: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Menarini:Expected (by end of conference) ; Consultant:Travere Therapeutics:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Boehringer and Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Alexion:Active (exists now) | Chiadi Ndumele: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Incretin Modulation: Is a New Standard of Care Emerging?

Monday, 11/18/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Discussant: FLOW

Rangaswami Janani, Deboer Ian, Vaduganathan Muthiah

Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial

Tuttle Katherine, Mann Johannes, Perkovic Vlado, Pratley Richard, Ridker Paul, Rossing Peter, Schmieder Roland, Shamkhalova Minara S., Sreenivasamurthy L, Mahaffey Kenneth, Bakris George, Bang Casper, Bax Willem, Belmar Nicolas, Brown Paul, Cherney David, Chernin Gil, Lim Soo Kun

More abstracts from these authors:
Overview of AHA CKM

Ndumele Chiadi

Cardiovascular Risk Prediction with the Kidney Failure Risk Equation Among Patients with Chronic Kidney Disease: Insights from CRIC

Correa Simon, Beldhuis Iris, Neuen Brendon, Vaduganathan Muthiah, Wilson F. Perry, Mc Causland Finnian

You have to be authorized to contact abstract author. Please, Login
Not Available